Table 2B. Potential adverse effects of a single oral administration of captan (Women who are or may be pregnant) .

Species	Study	Dose (mg/kg bw/day)	NOAEL(mg/kg bw/day) and critical endpoints1)
Rabbit	Developmental toxicity study (the 2nd study)	0, 10, 40, 160	Maternal: 40 Maternal: Increased embryo resorption and postimplantation loss
	Developmental toxicity study (the 3rd study)	0, 10, 30, 100	Maternal: 30 Embryo/fetus: 30 Maternal: Increase of postimplantation loss rate and the number of dead embryos Embryo/fetus: External, skeletal and soft tissue alterations
Hamster	Developmental toxicity study (the 1st study)	0, 50, 200, 400	Maternal: 200 Embryo/fetus: 200 Maternal: Increased embryo resorption and decreased the number of viable fetuses Embryo/fetus: Tail deformation, whole body edema, complex abnomalty, etc.
ARfD			NOAEL: 30 SF: 100 ARfD: 0.3
The critical study for setting ARfD			Developmental toxicity study in rabbits (the 3rd study)

ARfD, Acute reference dose; SF, Safety factor; NOAEL, No-observed-adverse-effect level

¹⁾ The adverse effect observed at the lowest-observed-adverse-effect level (LOAEL)